Back to Journals » Drug Design, Development and Therapy » Volume 3

Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty

Authors Lewis K, Eugster E

Published 23 December 2008 Volume 2009:3 Pages 1—5

DOI https://doi.org/10.2147/DDDT.S3298

Review by Single-blind

Peer reviewer comments 3


Katherine A Lewis, Erica A Eugster

Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, USA

Abstract: In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP). Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids. Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height. A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer. A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP. Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years. The most common adverse effects of the implant relate to implant site pain or bruising. Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide. While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

Keywords: central precocious puberty, histrelin, implant, gonadotropin-releasing-hormone analogs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]